OKYO Pharma Ltd. Form 6-K Summary
Business Context and Reporting Period
OKYO Pharma Ltd., a foreign private issuer filing annual reports on Form 20-F, furnished this Form 6-K on April 2, 2024. The filing concerns an upcoming presentation of Phase 2 data for OK-101 in dry eye disease at Eyecelerator 2024, held in conjunction with the American Society of Cataract and Refractive Surgery Annual Meeting on April 4, 2024, in Boston, Massachusetts.
Financial and Operating Metrics
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, cash balance, or other financial metrics.
Material Changes Versus Prior Period
The filing does not report financial or operating changes versus a prior comparable period. The principal disclosed development is the scheduled presentation of OK-101 Phase 2 dry-eye-disease data.
Guidance, Outlook, Risks, and Unusual Items
No formal financial guidance, commercialization outlook, risk update, contingency, or unusual financial item is provided in the filing text. The results and related commentary were to be presented at the April 4, 2024 event; the filing text does not include the Phase 2 data or its conclusions.
Key Facts for Investors to Verify
- Review Exhibit 99.1, the April 2, 2024 press release, for the company’s announcement and any details regarding the planned presentation.
- Verify the actual OK-101 Phase 2 data, endpoints, statistical results, safety findings, and management interpretation when available.
- Consult the company’s latest Form 20-F and other filings for financial position, cash runway, financing needs, and applicable risk factors.
- The exhibit is furnished rather than filed for purposes of Section 18 of the Securities Exchange Act and is not incorporated by reference into other filings unless expressly stated.